$113 BillionThe market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.
$198.64 - $268.39The lowest and highst price in the last 52 weeks.
20.2xThe price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.
$6.96 (3.46%)Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).
|Market Cap||$113 Billion|
|Enterprise Value||$138 Billion|
|Dividend Yield||$6.96 (3.46%)|
|1 Year Return||-5.0%|
|Outstanding Shares||563 Million|
|Avg 30 Day Volume||3.01 Million|
|Earnings per Share||$9.70|
|Price to Sales Ratio||4.7|
|Price to Book Ratio||15.09|
|Revenue to Enterprise Value||5.35|
|EBIT to Enterprise Value||15.59|
|Total Debt to Enterprise Value||0.27|
|Debt to Equity||4.57|
|Gross Profit||$19.4 Billion|
|Net Income||$5.61 Billion|
|Quarterly Earnings Growth (YoY)||-6.8%|
|Return on Equity||68.26%|
|Return on Assets||8.63%|
|Return on Invested Capital||17.64%|
13,360 shares sold (4 transactions)
2,750 shares sold (2 transactions)
CEO: Robert Bradway
Industry: Biological Product (except Diagnostic) Manufacturing
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
The global Colorectal Cancer Drugs market size is projected to a CAGR of 4.8% during 2021-2027. The colorectal malignant growth drugs market comprises the of...OpenPR, 8 days ago
THOUSAND OAKS, Calif., Nov. 29, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has been named to the Dow Jones Sustainability World Index f...PR Newswire, 9 days ago
Bard Financial Services Inc. reduced its position in Amgen Inc. (NASDAQ:AMGN) by 0.1% during the third quarter, HoldingsChannel.com reports. The institutiona...Dakota Financial News, 10 days ago
Equities analysts predict that Amgen Inc. (NASDAQ:AMGN) will announce $6.90 billion in sales for the current fiscal quarter, according to Zacks. Eight analys...Dakota Financial News, 10 days ago